Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Trevena stock

Own Trevena stock in just a few minutes.

Trevena, Inc is a biotechnology business based in the US. Trevena shares (TRVN) are listed on the NASDAQ and all prices are listed in US Dollars. Trevena employs 25 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Trevena

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – TRVN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Trevena share price

Use our graph to track the performance of TRVN stocks over time.

Trevena shares at a glance

Information last updated 2021-04-23.
52-week range$0.68 - $3.68
50-day moving average $1.90
200-day moving average $2.31
Wall St. target price$5.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.26

Buy Trevena shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Trevena stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Trevena financials

Revenue TTM $3.1 million
Gross profit TTM $2.9 million
Return on assets TTM -21.09%
Return on equity TTM -43.79%
Profit margin 0%
Book value $0.65
Market capitalisation $292.4 million

TTM: trailing 12 months

Shorting Trevena shares

There are currently 20.3 million Trevena shares held short by investors – that's known as Trevena's "short interest". This figure is 2% down from 20.8 million last month.

There are a few different ways that this level of interest in shorting Trevena shares can be evaluated.

Trevena's "short interest ratio" (SIR)

Trevena's "short interest ratio" (SIR) is the quantity of Trevena shares currently shorted divided by the average quantity of Trevena shares traded daily (recently around 3.2 million). Trevena's SIR currently stands at 6.41. In other words for every 100,000 Trevena shares traded daily on the market, roughly 6410 shares are currently held short.

However Trevena's short interest can also be evaluated against the total number of Trevena shares, or, against the total number of tradable Trevena shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Trevena's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 Trevena shares in existence, roughly 130 shares are currently held short) or 0.1274% of the tradable shares (for every 100,000 tradable Trevena shares, roughly 127 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Trevena.

Find out more about how you can short Trevena stock.

Trevena share dividends

We're not expecting Trevena to pay a dividend over the next 12 months.

Trevena share price volatility

Over the last 12 months, Trevena's shares have ranged in value from as little as $0.6801 up to $3.68. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Trevena's is 2.5207. This would suggest that Trevena's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Trevena overview

Trevena, Inc. , a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist that has completed Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site